Navigation Links
Volcano Reports 22 Percent Increase in Third Quarter Revenues
Date:11/5/2009

healthcare. We believe this data will help fuel further adoption of our current and future products," Huennekens concluded.

2009 Guidance

The company reconfirmed prior guidance for fiscal 2009 and continues to expect revenues for fiscal 2009 will be in the range of $218-$223 million, or an increase of 27-30 percent over revenues in 2008.

The company continues to expect gross margin for the full year will be in the range of 59-60 percent, including additional depreciation of approximately $775,000 through the balance of the year related to the distributor transition in Japan. Operating expenses continue to be expected in the range of 67-69 percent, including stock-based compensation expense of approximately $12.0 million, intangible amortization of approximately $4.2 million and approximately $3.5 million in Goodman commissions. The outlook for operating expenses reflects increased spending in Japan, the expansion of sales and marketing programs in other geographies, G&A to support the growth of the company and litigation-related expenses. The company also expects a modest increase in research and development spending to fund product development programs, clinical trials and regulatory activities.

The company continues to expect to report a GAAP net loss of $0.38-$0.43 per share. Excluding stock-based compensation expense of approximately $12.0 million and Goodman commissions of approximately $3.5 million, the company expects to report a net loss of $0.06-$0.11 per share. The company further noted that as previously reported, additional payments would be due to former CardioSpectra stockholders if one of the specific milestones in the acquisition agreement is met by the end of fiscal 2009 and the company would be required to make a milestone payment of approximately $11.0 million and record a one-time charge to in-process research and development. The impact of this charge, if it were to occur, would increase expectat
'/>"/>

SOURCE Volcano Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Volcano Corporation Announces Proposed Public Offering of Common Stock
2. Volcano Corporation Reports Preliminary Third Quarter 2007 Revenues
3. Volcano Reports Record Third Quarter Revenues
4. Volcano Corporation Presentation at Piper Jaffray Conference to be Webcast
5. Volcano Corporation Selects Xactly to Drive Strategic Sales Performance Management
6. Volcano Reports 35 Percent Increase in Quarterly Revenues; IVUS Disposable Revenues Increase 46 Percent
7. Chilean volcano captured blasting ash
8. Volcano Corporation Presentation at JMP Conference to be Webcast
9. Volcano Presentation at Canaccord Adams Conference to be Webcast
10. Volcano Corporation Announces the Relocation of Corporate Headquarters to San Diego
11. Volcano Reports 40 Percent Growth in Quarterly Revenues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... 07, 2015 , ... RadSiteā„¢, a leading accreditation agency for ... for Medicare and Medicaid Services (CMS), announces that it has updated its website ... The most effective websites are those that provide timely information, frequent updates and ...
(Date:7/7/2015)... ... July 07, 2015 , ... Connexion Point is holding an onsite job fair to hire ... 1769 Paragon Place, Suite 100, this upcoming Wednesday, July 8, and Thursday, July 9, from ... will be recruiting new applicants as well as holding onsite interviews. Interested parties are ...
(Date:7/6/2015)... ... 2015 , ... Currently, mobile testing is one the fastest ... the molecular diagnostic technologies, wide availability of immunosuppressive drugs and bioterrorism threats are ... engineering also open lucrative opportunities for the market players. , However, there are ...
(Date:7/6/2015)... ... July 06, 2015 , ... University of Pittsburgh Cancer Institute (UPCI) ... testing to reflect newly available tests that better incorporate personalized medicine into diagnosing the ... thyroid cancer tests is published in the July issue of the scientific journal ...
(Date:7/6/2015)... NY (PRWEB) , ... July 06, 2015 , ... ... health care from nurses or midwives, yet there is a large gap between ... and midwifery research required to improve health outcomes and reduce unnecessary or ineffective ...
Breaking Medicine News(10 mins):Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 2Health News:RadSite Releases Mobile-friendly Website for Enhanced User Experience 3Health News:Connexion Point, a tech enabled healthcare services company, is holding on-site job fair July 8th and 9th to fill 400 positions at its new Memphis location 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 2Health News:World Infectious Disease Testing Market Examined by VPGMarketResearch.com in In-Demand Report Available at MarketPublishers.com 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 2Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 3Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 4Health News:Pitt Scientists Lead Consensus Guidelines for Thyroid Cancer Molecular Tests 5Health News:Columbia Nursing Nairobi Summit: Setting a Clinical Research Agenda for Africa 2
... team of researchers, including a number from the University of ... regions of the genome that contribute to the debilitating lung ... Their findings provide insight into the causes of the wide ... also points the way to new diagnostic markers and therapeutic ...
... , MONDAY, May 23 (HealthDay News) -- Cancer patients who ... greater sense of satisfaction about their treatment, a new study ... and accurate medical information built trust between patient and doctor. ... , the study analyzed 295 patients recently diagnosed with lymphoma, ...
... Monday, May 23, 2011 New findings out of Wake Forest ... in predicting early death in individuals with diabetes. ... Care . "People with diabetes are already at high risk ... W. Bowden, Ph.D., the director of the Center for Diabetes Research ...
... 22, 2011- Gothenburg, Sweden : The aldosterone antagonist ... new onset atrial fibrillation and flutter (AFF) in ... sub-analysis of the EMPHASIS-HF trial, presented at the ... Failure Association of the European Society of Cardiology ...
... Although chemotherapy is used to kill cancer cells, it ... such as bone marrow and blood cells, often limiting the ... Fred Hutchinson Cancer Research Center reported at today,s annual meeting ... Seattle that one possible approach to reduce this toxic effect ...
... , FRIDAY, May 20 (HealthDay News) -- The ... skin -- is significantly higher among overweight and obese kids, ... online in the Journal of Pediatrics , also found ... higher cholesterol levels, putting them at greater risk for heart ...
Cached Medicine News:Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 2Health News:Consortium identifies genome regions that could influence severity of cystic fibrosis 3Health News:Cancer Patients Benefit From Full Access to Medical Records 2Health News:Common test could help predict early death in diabetes, study shows 2Health News:Common test could help predict early death in diabetes, study shows 3Health News:EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation 2Health News:EMPHASIS HF: Study shows epleronone to reduce atrial fibrillation 3Health News:Gene-modified stem cells help protect bone marrow from toxic side effects of chemotherapy 2Health News:Study Sees Link Between Psoriasis, Obesity in Kids 2
(Date:7/6/2015)... 2015 Celtaxsys, Inc., a clinical stage pharmaceutical ... rare and orphan inflammatory disease indications, announced today that ... Drug Administration (FDA) to begin a Phase 2 clinical ... adult CF patients in the US. The regulatory submissions ... will be filed soon after. This groundbreaking clinical ...
(Date:7/6/2015)... SOUTH SAN FRANCISCO, Calif. , July 6, 2015 ... leading global pharmaceutical company, and Oculeve, a development-stage medical ... eye disease, today announced that they have entered into ... an all-cash transaction.  Under the terms of the agreement, ... payment and commercialization milestone payments related to Oculeve,s lead ...
(Date:7/6/2015)... SHENZHEN, China , July 6, 2015 China ... CNIT), a leading provider of integrated cloud-based platform, exchange, ... , today announced that the Company launched its mobile ... age of accessible healthcare services on mobile devices. The ... District Health and Family Planning Bureau and Shenzhen News ...
Breaking Medicine Technology:Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 2Allergan to Acquire Oculeve Dry Eye Disease Development Programs 3Allergan to Acquire Oculeve Dry Eye Disease Development Programs 4CNIT Launches the Mobile App for Healthcare One Pass 2CNIT Launches the Mobile App for Healthcare One Pass 3CNIT Launches the Mobile App for Healthcare One Pass 4
... 8 Cell Therapeutics, Inc. (CTI),(Nasdaq and ... data for the,Zevalin(R) ([90Y]-ibritumomab tiuxetan) First-line Indolent ... Hematology (ASH) 50th Annual Meeting by,Morschhauser, et ... (PFS) following Zevalin consolidation therapy for patients ...
... Patients with non-valvular,atrial fibrillation receiving either 30 mg ... oral Factor Xa inhibitor, experienced comparable,safety and tolerability ... II data presented today at the 50th Annual ... Francisco. These findings are the first results,from ...
Cached Medicine Technology:Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 2Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 3Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 4Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months 5New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 2New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 3New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 4New Phase II Data Show Safety of Once-Daily Oral Factor Xa Inhibitor, DU-176b, Comparable to Warfarin in Patients With Non-Valvular Atrial Fibrillation 5
... white LED (Light Emitting Diode) light source, coupled ... the freedom of using a slit lamp anywhere ... about 1.5 lbs. (0.68 kg) with its battery ... Its ergonomic, portable design and convenient carrying ...
Powerful LED Illumination , The ultrabright and compact 3S LED HeadLight from HEINE for Powerful, coaxial illumination...
... Abnormal Control Serum is intended for monitoring the ... assays. It is for in vitro diagnostic use ... format, the control offers up to ten days ... control is to be used in accordance with ...
e-MDs Bill practice management system is used in the medical billing cycle....
Medicine Products: